2022 Continuing Education Credits

Registrants are responsible for confirming that credits earned will be accepted for their specified certification by the appropriate accrediting body.

Attendance at conference events will be verified electronically. Each attendee seeking continuing education credits/hours will need to complete an evaluation for each session attended. Your login credentials will be used to track and tabulate each attendee’s continuing education credits/hours. After the conference, certificates documenting attendance and the number of continuing education credits/hours earned will be electronically generated and emailed to all eligible attendees. Questions concerning Continuing Education Credits may be directed to meetings@aatod.org.

To access your credits, click here.

CONTINUING EDUCATION HOURS OFFE RED For a complete listing of hours offered, click here.

2022 CONTINUING EDUCATION HOURS (CEH) CREDIT

ASWB-AATOD, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB), www.aswb.org, through the Approved Continuing Education (ACE) program. The American Association for the Treatment of Opioid Dependence (AATOD) maintains responsibility for the program. ASWB Approval Period: 6/12/2022-6/12/2025. Social workers should contact their regulatory board to determine course approval. Social workers participating in this course will receive up to 34.5 (clinical or social work ethics) continuing education clock hours. Please view the Conference Program for more information on specific learning outcomes and objectives, the target audience and the number of credit hours awarded for all conference sessions from ASWB. NAADAC-AATOD is an approved single event provider with

NAADAC, provider number 62794, offering credits for counselors. NAADAC provider status expires on January 31, 2024 for the AATOD 2022 Conference for up to 34.5 CE Credits.

ADACBGA – AATOD is an approved provider with the Alcohol & Drug Abuse Certification Board of Georgia (IC&RC Affiliate), provider number 2022-09-003, offering credits for counselors.

2022 CONTINUING NURSING EDUCATION (CNE) CREDIT NEMSD-This continuing nursing education activity was approved by the Northeast Multistate Division, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

NEMSD Approver Unit has Approved Continuing Nursing Education Activity, AATOD 2022 Conference for October 30- November 3, 2022, for 34.5 Contact Hours. 2022 CONTINUING MEDICAL EDUCATION (CME) CREDIT AMA Credit Designation Statement:
The American Society of Addiction Medicine designates this live activity for a maximum of 33.50 AMA PRA

Category 1 Credit (s) rM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American Society of Addiction Medicine (ASAM) and the American Association for the Treatment of Opioid Dependence, Inc. The American Society of Addiction Medicine is accredited by the ACCME to provide continuing medical education for physicians. Disclosure Information
In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. These policies include mitigating all relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CE Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

 

CME Committee Reviewer
Catharina Armstrong, MD, FASAM – No relevant financial disclosures
Cara A. Poland, MD, MEd, DFASAM – No relevant financial disclosures
R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM – No relevant financial disclosures
Herbert L. Malinoff, MD, FACP, DFASAM – No relevant financial disclosures
Noel llogu, MD, MRCP, FASAM – No relevant financial disclosures Presenters
Aaron Greenblatt, MD – No relevant financial disclosures
Adam Lewis, JD – No relevant financial disclosures
Aditi Ringwala, MD – No relevant financial disclosures
Alain Litwin, MD, MPH – No relevant financial disclosures
Alan Nolan, LCSW – No relevant financial disclosures
Allison Thomson, MPH – No relevant financial disclosures
Ally Lor, RN, CARN – No relevant financial disclosures
Andre Jean Remy, MD – No relevant financial disclosures
Andrea Walker, MA, MPH – No relevant financial disclosures
Andrew Schreier, ICS – No relevant financial disclosures
Andrew Stone, MD – No relevant financial disclosures
Andrew Talal, MD, MPH – No relevant financial disclosures
Anita Kennedy, BS CRPA CMA – No relevant financial disclosures
Anna Stewart, MBA- No relevant financial disclosures
Annabelle (Mimi) Belcher, PhD – No relevant financial disclosures
Anne Ruble, MD, MPH – No relevant financial disclosures
Anthony Folland, BA- No relevant financial disclosures
Arthur McFarlane, MS – No relevant financial disclosures
Ashton Marra, MS – No relevant financial disclosures
Babak lmanoel, DO- No relevant financial disclosures
Beth Rutkowski, MPH – No relevant financial disclosures
Brandee Izquierdo, DPA, MPA, CPRS – No relevant financial disclosures
Brenda Davis, MSW, CASAC-T, CMA – No relevant financial disclosures
Brian Myers, MBA, MTS, CMPE – No relevant financial disclosures
Brittania Liebla, DNP – No relevant financial disclosures
Carla Carter, JD – No relevant financial disclosures
Casey Tiefenwerth, MSW – No relevant financial disclosures
Catherine Abrams, LMSW, CAC-AD, RPS – No relevant financial disclosures Charissa Patricelli, MD – No relevant financial disclosures
Chrissie Martin, LMFT, LACS, CS – No relevant financial disclosures
Christina Mazza, RPS, CPRS, CCHW – No relevant financial disclosures Christine Neeb, MD – No relevant financial disclosures
Christine Scalise, MA, LPG, LCADC – No relevant financial disclosures Colleen Flanigan, RN, MS – No relevant financial disclosures
Dana Heilman, BS, MSW, MPH – No relevant financial disclosures
Daniel Barden, MS – No relevant financial disclosures
Darren McGregor, MS, MHS, LCMFT – No relevant financial disclosures David Whitesock – Does Disclose Commonly Well (Salary/Stockholder)
Deborah Reid, JD – No relevant financial disclosures
Deena Murphy, PhD – No relevant financial disclosures
Desmond Haneef – Perry, PRS – No relevant financial disclosures
Dona Dmitrovic, MHS – No relevant financial disclosures
Ed Soffe, LCSW-C – No relevant financial disclosures
Edward Long, AB, MA, PhD – No relevant financial disclosures
Elizabeth Connolly, MPA – No relevant financial disclosures
Ellen Weber, JD – No relevant financial disclosures
Emily Hosea – No relevant financial disclosures
Eric Schwartz, MD, MBA – No relevant financial disclosures
Eric Weintraub, MD – No relevant financial disclosures
Ericka Stropka, BS – No relevant financial disclosures
Faye Taxman, PhD – No relevant financial disclosures
Filippo Della Rocca – No relevant financial disclosures
Frances McGaffey, MPP – No relevant financial disclosures
G. Malik Burnett, MD, MBA, MPH – No relevant financial disclosures
Gabrielle de la Gueronniere, JD – No relevant financial disclosures
Gina Zaccagnino, LCSW – No relevant financial disclosures
Gregory Branch, MD, MBA, CPE – No relevant financial disclosures
Heather Raley, LCPC – No relevant financial disclosures
Hedi Levine, PhD – No relevant financial disclosures
Holly Hagle, PhD – No relevant financial disclosures
James Anderson, PA-C – No relevant financial disclosures
James Yoe, PhD – No relevant financial disclosures
Jason Kletter – Does Disclose BayMark Health Services (Employment) Salary
Jeffrey Hsu, MD – No relevant financial disclosures
Jessica Blose, LMHC, SUDP, NCC, CCMHC – No relevant financial disclosures John Brooklyn, MD – No relevant financial disclosures
John Hamilton, LMFT, LADC – No relevant financial disclosures
John McCarthy, MD – No relevant financial disclosures
Jonathan Stoltman, PhD – No relevant financial disclosures
Joshua Nirella, MS – No relevant financial relationships
Julie Achtyl, MS, LMHC, Master CASAC, NCC, ACS – No relevant financial disclosures Justin Berk, MD, MPH, MBA – No relevant financial disclosures
Kate Dunn, MSN, RN, CNL – No relevant financial disclosures
Katherine Findley, PhD, MSW – No relevant financial disclosures
Kathleen Rebbert-Franklin, LCSW-C – No relevant financial disclosures
Kathryn Cates-Wessel – No relevant financial disclosures
Katie Rouse, BA – No relevant financial disclosures
Kelly Coble, LCSW-C – No relevant financial disclosures
Kenneth Stoller – Does Disclose Berkshire Biomedical LLC (Consulting)
Kenny House, LCAS, CCS – No relevant financial disclosures
Kirsten Forseth, MPH – No relevant financial disclosures
Kisha Winston-Watkins, MBA, LCSW-C – No relevant financial disclosures
Kristi O’Malley, JD – No relevant financial disclosures
Krysten Garcia, BA – No relevant financial disclosures
Larry Onate, MD – No relevant financial disclosures
Latonya Adjei-Tabi, MPA – No relevant financial disclosures
Laura Maroldo – Does Disclose- AbbVie (Consulting) & Gilead (Speakers Bureau)
Laurie Krom, MS – No relevant financial disclosures
Linda Hurley, MA – No relevant financial disclosures
Lori Canane, LADC II – No relevant financial disclosures
Marc Fishman – Does Disclose Alkermes (Consulting) (Products/Services: Extended-release naltrexone) (Consulting Fees (e.g., advisory boards), research grant) Drug Delivery LLC (Consulting) (Products/Services: naltrexone implant) (Consulting Fees (e.g., advisory boards)
Margaret Marcello, BSN, RN, PMH-BC – No relevant financial disclosures
Maria Bruni, PhD – No relevant financial disclosures
Marian Currens, CRNP – No relevant financial disclosures
Marie Stratton, CHRS – No relevant financial disclosures
Mark Kraus, MD – No relevant financial disclosures
Mark Parrino, MPA – No relevant financial disclosures
Marla Oros, RN, MS, FAAN – No relevant financial disclosures
Mary Ann Thompson – No relevant financial disclosures
Mary Keller, MA – No relevant financial disclosures
Matthew Burgan, MD – No relevant financial disclosures
Maureen O’Neill Biggs, MSW, LCSW – No relevant financial disclosures
Meaghan Elliott, BS – No relevant financial disclosures
Megan Marx, MPA, NCPRSS – No relevant financial disclosures
Michael Gordon – Does Disclose Alkermes (Other Activities) (Products/Services: Study drug (VIVITROL) donation for NIDA/NIH study)
(Honoraria, Study drug) Braeburn (Other Activities) (Products/Services: study drug (BRIXADI/BUVADIL) for NIH/NIDA funded study) (Honoraria, Study drug) MedicaSafe (Other Activities) (Products/Services: Medication dispensing device for NIH/NIDA funded study) (Honoraria, medication dispensing device)
Michael Kidorf, PhD – No relevant financial disclosures
Michael Litterer, CHES, CPS, FHELA – No relevant financial disclosures
Michael Miller – Does Disclose US WorldMeds (Consulting) (Consulting Fees (e.g., advisory boards)
Michelle Byron, LPN – No relevant financial disclosures
Michelle Lalinde – No relevant financial disclosures
Michelle Marshall – No relevant financial disclosures
Miriam Delphin-Rittmon, PhD – No relevant financial disclosures
Mishka Terplan, MD – No relevant financial disclosures
Monica White, MS, CAC-AD, RPS – No relevant financial disclosures
Nancy Young, PhD – No relevant financial disclosures
Nicholas Van Dyke – Does Disclose BayMark Health Services (Employment)(Products/Services: Employee of company) (Salary) Nicole Augustine, MPH, MCHES, PS – No relevant financial disclosures
Patricia Precin, PhD – No relevant financial disclosures
Patti Juliana, PhD – No relevant financial disclosures
Rahul Gupta, MD, MPH, MBA, FACP – No relevant financial disclosures
Rebecca Trott, LCSW-C – No relevant financial disclosures
Rebekah Joab, JD – No relevant financial disclosures
Regina Gullette, PhD, LICDC-CS, MAC, SAP – No relevant financial disclosures
Robert Kent, JD – No relevant financial disclosures
Robin Rickard, JD – No relevant financial disclosures
Rosemarie Martin, PhD – No relevant financial disclosures
Ryan Mueller, MEd, LPC, LAC – No relevant financial disclosures
Sadie Smith, MSW – No relevant financial disclosures
Salima Montes, LCPC, CAC-AD – No relevant financial disclosures
Sara Gefvert, CRS/CPS, CMA – No relevant financial disclosures
Sarah Sweeney, MSW, MPH – No relevant financial disclosures
Shani Litwin, BA – No relevant financial disclosures
Sharif Nankoe, MD, MPA, MA, FASAM – No relevant financial disclosures
Sika Yeboah-Sampang, JD – No relevant financial disclosures
Steve Millette, MS – No relevant financial disclosures
Susan Hadley, MD – No relevant financial disclosures
Suzanne Borys, EdD – No relevant financial disclosures
Tara Kunkel, MSW – No relevant financial disclosures
Teri Morgan-Urie, CADCII – No relevant financial disclosures
Theresa Tassey, MD, MPH, MS – No relevant financial disclosures
Tina Masai – No relevant financial disclosures
Tracy Agee, NP – No relevant financial disclosures
Tracy Desruisseaux, LADC-1 – No relevant financial disclosures
Tracy Schulden, LCSW-C – No relevant financial disclosures
Tyrell Moyd, RPS, RCP- No relevant financial disclosures
Vanessa Baaklini, MSW – No relevant financial disclosures
Vickie Walters, LCSW-C – No relevant financial disclosures
Vinay Parekh, MD – No relevant financial disclosures
Yehoshua Mirkin – No relevant financial disclosures
Yngvild Olsen, MD, MPH – No relevant financial disclosures

Planning Committee
Kenneth Stoller, MD – Does disclose Berkshire Biomedical LLC (Consultant)
Susan A. Storti, PhD, RN, NEA-BC, CARN-AP – No relevant financial disclosures Holly Broce, MHA, LCADC – No relevant financial disclosures
Antoinette (Toni) Maynard-Carter – No relevant financial disclosures
Michael Rizzi – No relevant financial disclosures
Vickie L. Walters, LCSW-C – No relevant financial disclosures
Marian Currens CRNP Director – No relevant financial disclosures
Lillian Dannard, LCSW-C – No relevant financial disclosures
Robert C. Lambert, MA – No relevant financial disclosures
Barry Page – No relevant financial disclosures
Maria Ramos, CMP – No relevant financial disclosures
Brent Schwartz – No relevant financial disclosures
Tomell Harbison – No relevant financial disclosures
Mark W. Parrino, MPA – No relevant financial disclosures
Carleen Maxwell-Taylor – No relevant financial disclosures
Angelina Budija – No relevant financial disclosures
Sabrina Jones – No relevant financial disclosures

Visit the aatod conference website for more details…www.aatodconference.com.

@aatod1984
  • AVAILABLE 🗒️ 
TECHNICAL REVIEW OF SAMHSA’S FINAL REGULATIONS ➡️ bit.ly/3w71hOM

This brief can be used by treatment providers and state officials as a quick reference in better understanding the salient policy issues that are contained in SAMHSA's new regulations.

We certainly hope that this is helpful and please let us know if you have any questions.
  • View the latest #aatod2024 Conference Video Message from the Host Committee Chair, Katro Henderson. 

We look forward to seeing you next month in Las Vegas for the world’s premier training conference event for the Treatment of Opioid Use Disorder. #OUD #somuchmorethanmedication

https://youtu.be/i6u3qUS95jU
  • 💻 Access the 3/27 SAMHSA Webinar Recording on 42 CFR Part 8, Clinical ➡️ bit.ly/3TIEZdW.

#ICYMI This comprehensive webinar provided an overview of the rule changes and provided a discussion with SAMHSA regarding the implications of the changes.
  • 💻 Webinar Recording is Now Available
AATOD is pleased to share the March 20th SAMHSA Webinar Recording on 42 CFR Part 8, Administrative.  We encourage you to view this recording to assist you in determining how you will need to prepare for full implementation of these regulations. 

➡ https://youtu.be/pgWZUpDhi94?si=obomo4LXRIwJPiC8
  • 3/28 Expanding Access to #Methadone in Correctional Facilities will focus on opportunities to expand access to methadone in correctional facilities, including recent developments with the SAMHSA 2024 final rule on the use of methadone.

Register ➡️ bit.ly/3Vz1RPE
  • Invitation to SAMHSA Webinars on 42 CFR Part 8 💻 

On February 2, 2024, the final rule for 42 CFR Part 8 was published. The effective date for these regulations is April 2, 2024, with an implementation date of October 2, 2024. 

In preparation for implementation of the revisions, SAMHSA will provide two preliminary webinars for OTPs.  The first will focus on administrative areas; the second will focus more on clinical content. These will be held on March 20th (from 2-3pm EST) and March 27th, 2024 (from 2- 3pm EST).  

REGISTER ➡ https://conta.cc/3TF9CSQ

View the final rule ➡ https://lnkd.in/e_iu-AtG.

There will be an opportunity to receive an overview of the rule changes and discuss with SAMHSA the implications of the changes. 

We encourage you to attend these important meetings to assist you in determining how you will need to prepare for full implementation of these regulations. 

This webinar series will be moderated by Mark W. Parrino, MPA (AATOD President). Speakers include Yngvild Olsen, MD, MPH (Director - CSAT), Robert Baillieu, MD, MPH, FAAFP (Physician and Senior Advisor - SAMHSA/CSAT, and Patti Juliana, PhD, LCSW
(Director - CSAT’s Division of Pharmacologic Therapies).

The presentations will be followed by Q&A, and these webinars will become available to the public for On-Demand viewing via the AATOD website. Certificates of Attendance will be provided per request.
  • Don’t miss out on the chance to show your support, share your products/services and secure your sponsorship at the AATOD 2024 Conference, �The world’s premier training conference event for the Treatment of Opioid Use Disorder. #aatod2024

The 2024 AATOD Conference will attract over 1,600 physicians, social workers, nurses, counselors, program administrators, executive directors, and other treatment providers from many countries. The registrants are decision-makers with purchasing power for their treatment centers and are looking for new products, services, and information to improve their patient treatment.

To become an exhibitor today —> https://bit.ly/48ZKMRX
  • TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION

💻 View the latest Conference Video Message from AATOD's President, Mark W. Parrino bit.ly/48y815w,
for the most up-to-date details regarding the upcoming #aatod2024 Conference -
The world's premier training conference event for the treatment of Opioid Use Disorder. #OUD 

Registration ➡️ www.aatodconference.com
  • TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION #aatod2024

TODAY is the last day to take advantage of the discounted registration rate. #aatod2024 is the world’s premier training conference event for the treatment of #OUD.

For registration and hotel information ➡️ bit.ly/3Ue57Q6.

We look forward to seeing you in Las Vegas!
  • #aatod2024 Conference Update. Comprehensive Listing/Descriptions of Workshops, Posters, and Hot Topic Roundtable Conference Sessions are now available ➡️ http://bit.ly/3Ue57Q6.

The workshop committee is pleased to present a dynamic workshop lineup that includes extremely rich and diverse educational content for all disciplines. You will hear from experts who will share the latest research and developments relating to opioid use disorders and treatment. The workshop lineup will include state of the art information on diverse areas of focus such as patient care and best practices, building community partnerships and collaborations, public policy and regulatory changes, workforce development, quality assurance, and financial reimbursement. There will be workshops that focus on emerging treatment trends and developments such as the fentanyl epidemic, mobile opioid treatment programs, regulatory changes, expansion of treatment services in rural areas, integrating treatment with the corrections systems, and integrating harm reduction initiatives. For those newer to the field or those who want a refresher on the basics, we have once again included a “Foundations” track which will include selections on the fundamentals of medication assisted treatment.

The conference will continue to be the world’s premier training and education event for the treatment of opioid use disorders.  We hope to see you in Las Vegas!
AVAILABLE 🗒️ 
TECHNICAL REVIEW OF SAMHSA’S FINAL REGULATIONS ➡️ bit.ly/3w71hOM

This brief can be used by treatment providers and state officials as a quick reference in better understanding the salient policy issues that are contained in SAMHSA's new regulations.

We certainly hope that this is helpful and please let us know if you have any questions.
AVAILABLE 🗒️ 
TECHNICAL REVIEW OF SAMHSA’S FINAL REGULATIONS ➡️ bit.ly/3w71hOM

This brief can be used by treatment providers and state officials as a quick reference in better understanding the salient policy issues that are contained in SAMHSA's new regulations.

We certainly hope that this is helpful and please let us know if you have any questions.
AVAILABLE 🗒️ 
TECHNICAL REVIEW OF SAMHSA’S FINAL REGULATIONS ➡️ bit.ly/3w71hOM

This brief can be used by treatment providers and state officials as a quick reference in better understanding the salient policy issues that are contained in SAMHSA's new regulations.

We certainly hope that this is helpful and please let us know if you have any questions.
AVAILABLE 🗒️ 
TECHNICAL REVIEW OF SAMHSA’S FINAL REGULATIONS ➡️ bit.ly/3w71hOM

This brief can be used by treatment providers and state officials as a quick reference in better understanding the salient policy issues that are contained in SAMHSA's new regulations.

We certainly hope that this is helpful and please let us know if you have any questions.
AVAILABLE 🗒️ 
TECHNICAL REVIEW OF SAMHSA’S FINAL REGULATIONS ➡️ bit.ly/3w71hOM

This brief can be used by treatment providers and state officials as a quick reference in better understanding the salient policy issues that are contained in SAMHSA's new regulations.

We certainly hope that this is helpful and please let us know if you have any questions.
AVAILABLE 🗒️ 
TECHNICAL REVIEW OF SAMHSA’S FINAL REGULATIONS ➡️ bit.ly/3w71hOM

This brief can be used by treatment providers and state officials as a quick reference in better understanding the salient policy issues that are contained in SAMHSA's new regulations.

We certainly hope that this is helpful and please let us know if you have any questions.
AVAILABLE 🗒️ 
TECHNICAL REVIEW OF SAMHSA’S FINAL REGULATIONS ➡️ bit.ly/3w71hOM

This brief can be used by treatment providers and state officials as a quick reference in better understanding the salient policy issues that are contained in SAMHSA's new regulations.

We certainly hope that this is helpful and please let us know if you have any questions.
AVAILABLE 🗒️ 
TECHNICAL REVIEW OF SAMHSA’S FINAL REGULATIONS ➡️ bit.ly/3w71hOM

This brief can be used by treatment providers and state officials as a quick reference in better understanding the salient policy issues that are contained in SAMHSA's new regulations.

We certainly hope that this is helpful and please let us know if you have any questions.
AVAILABLE 🗒️ 
TECHNICAL REVIEW OF SAMHSA’S FINAL REGULATIONS ➡️ bit.ly/3w71hOM

This brief can be used by treatment providers and state officials as a quick reference in better understanding the salient policy issues that are contained in SAMHSA's new regulations.

We certainly hope that this is helpful and please let us know if you have any questions.
AVAILABLE 🗒️ 
TECHNICAL REVIEW OF SAMHSA’S FINAL REGULATIONS ➡️ bit.ly/3w71hOM

This brief can be used by treatment providers and state officials as a quick reference in better understanding the salient policy issues that are contained in SAMHSA's new regulations.

We certainly hope that this is helpful and please let us know if you have any questions.
AVAILABLE 🗒️  TECHNICAL REVIEW OF SAMHSA’S FINAL REGULATIONS ➡️ bit.ly/3w71hOM This brief can be used by treatment providers and state officials as a quick reference in better understanding the salient policy issues that are contained in SAMHSA's new regulations. We certainly hope that this is helpful and please let us know if you have any questions.
1 week ago
View on Instagram |
1/10
View the latest #aatod2024 Conference Video Message from the Host Committee Chair, Katro Henderson. 

We look forward to seeing you next month in Las Vegas for the world’s premier training conference event for the Treatment of Opioid Use Disorder. #OUD #somuchmorethanmedication

https://youtu.be/i6u3qUS95jU
View the latest #aatod2024 Conference Video Message from the Host Committee Chair, Katro Henderson. We look forward to seeing you next month in Las Vegas for the world’s premier training conference event for the Treatment of Opioid Use Disorder. #OUD #somuchmorethanmedication https://youtu.be/i6u3qUS95jU
3 weeks ago
View on Instagram |
2/10
💻 Access the 3/27 SAMHSA Webinar Recording on 42 CFR Part 8, Clinical ➡️ bit.ly/3TIEZdW.

#ICYMI This comprehensive webinar provided an overview of the rule changes and provided a discussion with SAMHSA regarding the implications of the changes.
💻 Access the 3/27 SAMHSA Webinar Recording on 42 CFR Part 8, Clinical ➡️ bit.ly/3TIEZdW. #ICYMI This comprehensive webinar provided an overview of the rule changes and provided a discussion with SAMHSA regarding the implications of the changes.
3 weeks ago
View on Instagram |
3/10
💻 Webinar Recording is Now Available
AATOD is pleased to share the March 20th SAMHSA Webinar Recording on 42 CFR Part 8, Administrative.  We encourage you to view this recording to assist you in determining how you will need to prepare for full implementation of these regulations. 

➡ https://youtu.be/pgWZUpDhi94?si=obomo4LXRIwJPiC8
💻 Webinar Recording is Now Available AATOD is pleased to share the March 20th SAMHSA Webinar Recording on 42 CFR Part 8, Administrative. We encourage you to view this recording to assist you in determining how you will need to prepare for full implementation of these regulations. ➡ https://youtu.be/pgWZUpDhi94?si=obomo4LXRIwJPiC8
3 weeks ago
View on Instagram |
4/10
3/28 Expanding Access to #Methadone in Correctional Facilities will focus on opportunities to expand access to methadone in correctional facilities, including recent developments with the SAMHSA 2024 final rule on the use of methadone.

Register ➡️ bit.ly/3Vz1RPE
3/28 Expanding Access to #Methadone in Correctional Facilities will focus on opportunities to expand access to methadone in correctional facilities, including recent developments with the SAMHSA 2024 final rule on the use of methadone. Register ➡️ bit.ly/3Vz1RPE
1 month ago
View on Instagram |
5/10
Invitation to SAMHSA Webinars on 42 CFR Part 8 💻 

On February 2, 2024, the final rule for 42 CFR Part 8 was published. The effective date for these regulations is April 2, 2024, with an implementation date of October 2, 2024. 

In preparation for implementation of the revisions, SAMHSA will provide two preliminary webinars for OTPs.  The first will focus on administrative areas; the second will focus more on clinical content. These will be held on March 20th (from 2-3pm EST) and March 27th, 2024 (from 2- 3pm EST).  

REGISTER ➡ https://conta.cc/3TF9CSQ

View the final rule ➡ https://lnkd.in/e_iu-AtG.

There will be an opportunity to receive an overview of the rule changes and discuss with SAMHSA the implications of the changes. 

We encourage you to attend these important meetings to assist you in determining how you will need to prepare for full implementation of these regulations. 

This webinar series will be moderated by Mark W. Parrino, MPA (AATOD President). Speakers include Yngvild Olsen, MD, MPH (Director - CSAT), Robert Baillieu, MD, MPH, FAAFP (Physician and Senior Advisor - SAMHSA/CSAT, and Patti Juliana, PhD, LCSW
(Director - CSAT’s Division of Pharmacologic Therapies).

The presentations will be followed by Q&A, and these webinars will become available to the public for On-Demand viewing via the AATOD website. Certificates of Attendance will be provided per request.
Invitation to SAMHSA Webinars on 42 CFR Part 8 💻 On February 2, 2024, the final rule for 42 CFR Part 8 was published. The effective date for these regulations is April 2, 2024, with an implementation date of October 2, 2024. In preparation for implementation of the revisions, SAMHSA will provide two preliminary webinars for OTPs.  The first will focus on administrative areas; the second will focus more on clinical content. These will be held on March 20th (from 2-3pm EST) and March 27th, 2024 (from 2- 3pm EST).  REGISTER ➡ https://conta.cc/3TF9CSQ View the final rule ➡ https://lnkd.in/e_iu-AtG. There will be an opportunity to receive an overview of the rule changes and discuss with SAMHSA the implications of the changes. We encourage you to attend these important meetings to assist you in determining how you will need to prepare for full implementation of these regulations. This webinar series will be moderated by Mark W. Parrino, MPA (AATOD President). Speakers include Yngvild Olsen, MD, MPH (Director - CSAT), Robert Baillieu, MD, MPH, FAAFP (Physician and Senior Advisor - SAMHSA/CSAT, and Patti Juliana, PhD, LCSW (Director - CSAT’s Division of Pharmacologic Therapies). The presentations will be followed by Q&A, and these webinars will become available to the public for On-Demand viewing via the AATOD website. Certificates of Attendance will be provided per request.
1 month ago
View on Instagram |
6/10
Don’t miss out on the chance to show your support, share your products/services and secure your sponsorship at the AATOD 2024 Conference, �The world’s premier training conference event for the Treatment of Opioid Use Disorder. #aatod2024

The 2024 AATOD Conference will attract over 1,600 physicians, social workers, nurses, counselors, program administrators, executive directors, and other treatment providers from many countries. The registrants are decision-makers with purchasing power for their treatment centers and are looking for new products, services, and information to improve their patient treatment.

To become an exhibitor today —> https://bit.ly/48ZKMRX
Don’t miss out on the chance to show your support, share your products/services and secure your sponsorship at the AATOD 2024 Conference, �The world’s premier training conference event for the Treatment of Opioid Use Disorder. #aatod2024 The 2024 AATOD Conference will attract over 1,600 physicians, social workers, nurses, counselors, program administrators, executive directors, and other treatment providers from many countries. The registrants are decision-makers with purchasing power for their treatment centers and are looking for new products, services, and information to improve their patient treatment. To become an exhibitor today —> https://bit.ly/48ZKMRX
2 months ago
View on Instagram |
7/10
TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION

💻 View the latest Conference Video Message from AATOD's President, Mark W. Parrino bit.ly/48y815w,
for the most up-to-date details regarding the upcoming #aatod2024 Conference -
The world's premier training conference event for the treatment of Opioid Use Disorder. #OUD 

Registration ➡️ www.aatodconference.com
TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION 💻 View the latest Conference Video Message from AATOD's President, Mark W. Parrino bit.ly/48y815w, for the most up-to-date details regarding the upcoming #aatod2024 Conference - The world's premier training conference event for the treatment of Opioid Use Disorder. #OUD Registration ➡️ www.aatodconference.com
2 months ago
View on Instagram |
8/10
TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION #aatod2024

TODAY is the last day to take advantage of the discounted registration rate. #aatod2024 is the world’s premier training conference event for the treatment of #OUD.

For registration and hotel information ➡️ bit.ly/3Ue57Q6.

We look forward to seeing you in Las Vegas!
TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION #aatod2024 TODAY is the last day to take advantage of the discounted registration rate. #aatod2024 is the world’s premier training conference event for the treatment of #OUD. For registration and hotel information ➡️ bit.ly/3Ue57Q6. We look forward to seeing you in Las Vegas!
3 months ago
View on Instagram |
9/10
#aatod2024 Conference Update. Comprehensive Listing/Descriptions of Workshops, Posters, and Hot Topic Roundtable Conference Sessions are now available ➡️ http://bit.ly/3Ue57Q6.

The workshop committee is pleased to present a dynamic workshop lineup that includes extremely rich and diverse educational content for all disciplines. You will hear from experts who will share the latest research and developments relating to opioid use disorders and treatment. The workshop lineup will include state of the art information on diverse areas of focus such as patient care and best practices, building community partnerships and collaborations, public policy and regulatory changes, workforce development, quality assurance, and financial reimbursement. There will be workshops that focus on emerging treatment trends and developments such as the fentanyl epidemic, mobile opioid treatment programs, regulatory changes, expansion of treatment services in rural areas, integrating treatment with the corrections systems, and integrating harm reduction initiatives. For those newer to the field or those who want a refresher on the basics, we have once again included a “Foundations” track which will include selections on the fundamentals of medication assisted treatment.

The conference will continue to be the world’s premier training and education event for the treatment of opioid use disorders.  We hope to see you in Las Vegas!
#aatod2024 Conference Update. Comprehensive Listing/Descriptions of Workshops, Posters, and Hot Topic Roundtable Conference Sessions are now available ➡️ http://bit.ly/3Ue57Q6. The workshop committee is pleased to present a dynamic workshop lineup that includes extremely rich and diverse educational content for all disciplines. You will hear from experts who will share the latest research and developments relating to opioid use disorders and treatment. The workshop lineup will include state of the art information on diverse areas of focus such as patient care and best practices, building community partnerships and collaborations, public policy and regulatory changes, workforce development, quality assurance, and financial reimbursement. There will be workshops that focus on emerging treatment trends and developments such as the fentanyl epidemic, mobile opioid treatment programs, regulatory changes, expansion of treatment services in rural areas, integrating treatment with the corrections systems, and integrating harm reduction initiatives. For those newer to the field or those who want a refresher on the basics, we have once again included a “Foundations” track which will include selections on the fundamentals of medication assisted treatment. The conference will continue to be the world’s premier training and education event for the treatment of opioid use disorders. We hope to see you in Las Vegas!
3 months ago
View on Instagram |
10/10

OTPs offer life-saving care beyond methadone services. A recent study found that Hepatitis C virus treatment initiated through OTP telehealth visits resulted in faster adoption of direct-acting antiviral therapy and higher cure rates. Learn more: https://ow.ly/I1NQ50RcE9g

Load More...

#aatod2024 Conference – Las Vegas

COUNTDOWN

2024 Conference

AATOD, Inc.
225 Varick Street, Suite 402
New York, New York 10014

Contact Us
Phone : 212-566-5555
Email : info@aatod.org

Social Sharing
RSS
Follow by Email
Facebook
Twitter
YouTube
LinkedIn
Instagram
Stay Connected to AATOD